HALO is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Additionally, the company could be a top pick for growth investors. HALO has a Growth Style Score of B, forecasting year-over-year ...

In the past year, shares of Halozyme have rallied 65.8% against the industry’s decline of 3.5%. Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 18th. Analysts expect the company to announce ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at ...

NASDAQ HALO opened at $58.29 on Friday ... The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business’s 50-day simple moving average ...

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 18th. Analysts expect Halozyme Therapeutics to ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report ... for Halozyme Therapeutics’ current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Halozyme ...

In this article, we are going to take a look at where Halozyme Therapeutics, Inc. (NASDAQ:HALO) stands against the other cheap biotech stocks. Biotechnology stocks are among the most volatile in ...